Stock listing
NASDAQ:DARE Dare Bioscience, Inc. Stock
Home listing (NASDAQ) of Dare Bioscience, Inc.
Follow Dare Bioscience, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:DARE
$0.407 USD -0.043 (-9.5%)
Close on Nov 20, 2026
- Day range
- $0.407 – $0.487 USDNov 20, 2026
- Volume
- 173,237 sharesNov 20, 2026
- Market cap
- $8.01M USDAt the close on Nov 20, 2026 · price × 19.67M shares outstanding
- 52-week range
- $0.407 – $3.780 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $179,764 USDMedian day 165,800 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:DARE · Home | $0.407 USD | -0.043 (-9.5%) | 173,237 | $0.450 | $0.487 | $0.407 | $0.450 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:DARE · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.407 | -0.043 | -9.5% | $0.450 | $0.487 | $0.407 | 173,237 | |
| $0.450 | +0.021 | +4.9% | $0.436 | $0.510 | $0.420 | 295,366 | |
| $0.429 | -0.155 | -26.6% | $0.580 | $0.588 | $0.415 | 923,226 | |
| $0.584 | -0.073 | -11.1% | $0.694 | $0.700 | $0.584 | 201,443 | |
| $0.657 | +0.013 | +2.0% | $0.650 | $0.695 | $0.630 | 74,397 | |
| $0.644 | -0.050 | -7.2% | $0.680 | $0.700 | $0.640 | 39,728 | |
| $0.694 | +0.002 | +0.3% | $0.709 | $0.715 | $0.690 | 97,900 | |
| $0.692 | +0.012 | +1.8% | $0.699 | $0.710 | $0.678 | 160,700 | |
| $0.680 | +0.041 | +6.4% | $0.651 | $0.680 | $0.640 | 102,900 | |
| $0.639 | +0.015 | +2.4% | $0.632 | $0.650 | $0.620 | 53,000 | |
| $0.624 | -0.038 | -5.7% | $0.669 | $0.680 | $0.610 | 146,600 | |
| $0.662 | +0.012 | +1.8% | $0.660 | $0.690 | $0.630 | 228,300 | |
| $0.650 | -0.005 | -0.8% | $0.653 | $0.660 | $0.620 | 138,900 | |
| $0.655 | -0.045 | -6.4% | $0.739 | $0.739 | $0.646 | 206,300 | |
| $0.700 | +0.018 | +2.6% | $0.703 | $0.703 | $0.670 | 651,500 | |
| $0.682 | +0.002 | +0.3% | $0.670 | $0.698 | $0.664 | 46,800 | |
| $0.680 | +0.017 | +2.6% | $0.680 | $0.680 | $0.663 | 46,100 | |
| $0.663 | +0.019 | +3.0% | $0.643 | $0.684 | $0.643 | 51,600 | |
| $0.644 | -0.002 | -0.3% | $0.668 | $0.675 | $0.640 | 50,500 | |
| $0.646 | -0.006 | -0.9% | $0.640 | $0.666 | $0.638 | 56,500 | |
| $0.652 | -0.036 | -5.2% | $0.685 | $0.713 | $0.625 | 327,900 | |
| $0.688 | -0.001 | -0.1% | $0.680 | $0.712 | $0.673 | 24,600 | |
| $0.689 | -0.017 | -2.4% | $0.723 | $0.730 | $0.670 | 217,700 | |
| $0.706 | -0.019 | -2.6% | $0.727 | $0.738 | $0.680 | 252,000 | |
| $0.725 | -0.015 | -2.0% | $0.739 | $0.740 | $0.713 | 77,200 | |
| $0.740 | +0.011 | +1.5% | $0.730 | $0.746 | $0.720 | 96,900 | |
| $0.729 | -0.019 | -2.5% | $0.743 | $0.743 | $0.720 | 61,000 | |
| $0.748 | -0.002 | -0.3% | $0.786 | $0.786 | $0.730 | 116,100 | |
| $0.750 | -0.023 | -3.0% | $0.770 | $0.790 | $0.738 | 81,600 | |
| $0.773 | +0.001 | +0.1% | $0.790 | $0.790 | $0.760 | 69,600 | |
| $0.772 | -0.018 | -2.3% | $0.786 | $0.800 | $0.755 | 165,800 | |
| $0.790 | -0.043 | -5.2% | $0.814 | $0.819 | $0.790 | 113,200 | |
| $0.833 | -0.010 | -1.2% | $0.830 | $0.880 | $0.830 | 88,400 | |
| $0.843 | 0.000 | 0.0% | $0.833 | $0.869 | $0.831 | 157,200 | |
| $0.843 | -0.008 | -0.9% | $0.869 | $0.878 | $0.822 | 147,300 | |
| $0.851 | -0.002 | -0.2% | $0.860 | $0.870 | $0.830 | 134,800 | |
| $0.853 | +0.038 | +4.7% | $0.800 | $0.880 | $0.768 | 277,700 | |
| $0.815 | +0.065 | +8.7% | $0.787 | $0.867 | $0.736 | 644,400 | |
| $0.750 | -0.026 | -3.4% | $0.790 | $0.816 | $0.701 | 697,300 | |
| $0.776 | +0.035 | +4.7% | $0.770 | $0.790 | $0.746 | 119,100 | |
| $0.741 | -0.066 | -8.2% | $0.802 | $0.846 | $0.712 | 469,500 | |
| $0.807 | -0.043 | -5.1% | $0.850 | $0.870 | $0.800 | 99,700 | |
| $0.850 | +0.040 | +4.9% | $0.810 | $0.880 | $0.810 | 245,500 | |
| $0.810 | +0.026 | +3.3% | $0.820 | $0.840 | $0.796 | 279,900 | |
| $0.784 | +0.036 | +4.8% | $0.793 | $0.810 | $0.766 | 229,200 | |
| $0.748 | +0.022 | +3.0% | $0.745 | $0.776 | $0.745 | 153,200 | |
| $0.726 | -0.004 | -0.5% | $0.732 | $0.759 | $0.724 | 135,400 | |
| $0.730 | -0.006 | -0.8% | $0.741 | $0.771 | $0.720 | 107,200 | |
| $0.736 | +0.030 | +4.2% | $0.706 | $0.750 | $0.691 | 426,100 | |
| $0.706 | +0.001 | +0.1% | $0.717 | $0.723 | $0.705 | 93,700 | |
| $0.705 | -0.012 | -1.7% | $0.700 | $0.725 | $0.700 | 102,500 | |
| $0.717 | +0.004 | +0.6% | $0.729 | $0.730 | $0.691 | 173,400 | |
| $0.713 | -0.008 | -1.1% | $0.730 | $0.737 | $0.701 | 191,700 | |
| $0.721 | +0.008 | +1.1% | $0.700 | $0.757 | $0.700 | 437,500 | |
| $0.713 | -0.027 | -3.6% | $0.751 | $0.779 | $0.690 | 450,300 | |
| $0.740 | -0.030 | -3.9% | $0.780 | $0.797 | $0.740 | 246,900 | |
| $0.770 | +0.009 | +1.2% | $0.744 | $0.797 | $0.730 | 461,200 | |
| $0.761 | +0.026 | +3.5% | $0.760 | $0.820 | $0.730 | 639,300 | |
| $0.735 | -0.004 | -0.5% | $0.758 | $0.758 | $0.720 | 354,200 | |
| $0.739 | -0.012 | -1.6% | $0.751 | $0.780 | $0.730 | 428,500 | |
| $0.751 | -0.070 | -8.5% | $0.833 | $0.847 | $0.740 | 952,200 | |
| $0.821 | +0.019 | +2.4% | $0.818 | $0.854 | $0.800 | 618,671 | |
| $0.802 | -0.018 | -2.3% | $0.820 | $0.845 | $0.800 | 434,896 | |
| $0.820 | +0.011 | +1.4% | $0.800 | $0.850 | $0.800 | 345,600 | |
| $0.809 | -0.015 | -1.8% | $0.820 | $0.860 | $0.780 | 502,500 |
Splits
2 splits since 2017 · NASDAQ:DARE · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-12 | Consolidation | |
| 1-for-10 | Consolidation |
- Ticker
- NASDAQ:DARE
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 16, 2026
Daré Bioscience Reports Third Quarter 2026 Financial Results and Highlights Commercial Execution and Pipeline Advancement
Latest earnings call · Nov 16, 2026
Dare Bioscience (NASDAQ:DARE) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Oct 1, 2026
Investor Presentation (October 2026)
Investor deck · 40 slides
Latest news
Daré Bioscience Reports Third Quarter 2026 Financial Results and Highlights Commercial Execution and Pipeline Advancement
Nov 16, 2026
Closed $0.429 (-26.6%) on Nov 17, 2026
Daré Bioscience Receives Approximately $852,000 in Additional Grant Funding
Nov 16, 2026
Closed $0.584 (-11.1%) on Nov 16, 2026
Daré Bioscience to Host Third Quarter 2026 Financial Results and Company Update Conference Call and Webcast on November 16, 2026
Nov 10, 2026
Closed $0.692 (+1.8%) on Nov 10, 2026
Daré Bioscience Releases Next Episode in “CEO Corner” Video Series
Nov 9, 2026
Closed $0.68 (+6.4%) on Nov 9, 2026
Daré Bioscience to Present at Stifel’s 2026 Healthcare Conference
Nov 4, 2026
Closed $0.662 (+1.8%) on Nov 4, 2026
Daré Bioscience Surpasses $43 Million in Non-Dilutive Grant Funding as Investigational Programmable Drug Delivery Platform Gains Momentum
Oct 30, 2026
Closed $0.70 (+2.6%) on Oct 30, 2026
Daré Bioscience Addresses New National Focus on Women’s Health in Virtual Investor “What This Means” Discussion
Oct 28, 2026
Closed $0.68 (+2.6%) on Oct 28, 2026
Daré Bioscience to Showcase Its Investigational Programmable Device, DARE-IDDS, at PODD 2026: One Device, Designed to Deliver 100+ Doses and to be Controlled Wirelessly
Oct 26, 2026
Closed $0.644 (-0.3%) on Oct 26, 2026
Daré Bioscience Sponsors HERmedicine Educational Program for Clinicians on Managing Menopause After Breast Cancer
Oct 19, 2026
Closed $0.706 (-2.6%) on Oct 19, 2026
Dare Bioscience, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 42 in the last 12 months · 186 in all · newest Nov 16, 2026 · oldest 2019
- Calls
- 26 calls with a replay · 26 with a transcript · latest Nov 16, 2026
- Decks
- 55 decks · latest Oct 1, 2026
Where Dare Bioscience, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:DARE · Home listing · This page | NASDAQ | United States | USD |
| BOATS:DARE | BOATS | United States | USD |
Valuation
EV/sales −1.9× against a median of 6.5×: the lowest of 3 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$2.65M USD
- P/E
- Loss
- EV/sales
- −1.9×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 3.4×
- Gross margin
- −12.9%
- Operating margin
- −746.1%
- Net margin
- −749.8%
- Debt to equity
- 0.4×
- Beta vs S&P 500
- 1.34
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Dare Bioscience, Inc. · NASDAQ:DARE | US$8.01M | −US$2.65M | n/a | −1.9× | n/a | 3.4× | −749.8% | 0.4× | 1.34 |
| Brainstorm Cell Therapeutics Inc. · OTC:BCLI | US$8.31M | US$10.08M | n/a | n/a | n/a | n/a | n/a | n/a | 0.40 |
| Quantum Biopharma Ltd. Subordinate Voting Shares Class B · NASDAQ:QNTM | US$8.29M | −US$3.20M | n/a | n/a | n/a | 0.7× | n/a | 0.1× | 1.05 |
| Moleculin Biotech, Inc. · NASDAQ:MBRX | US$8.22M | US$1.04M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | 0.42 |
| IN8bio, Inc. · NASDAQ:INAB | US$8.19M | −US$3.03M | n/a | n/a | n/a | 0.6× | n/a | 0.2× | 1.25 |
| Intensity Therapeutics, Inc. · NASDAQ:INTS | US$8.19M | −US$220,086 | n/a | n/a | n/a | 1.1× | n/a | 0.0× | 1.30 |
| Palatin Technologies, Inc. · AMEX:PTN | US$8.16M | US$4.58M | n/a | 12.7× | n/a | 4.0× | n/a | 0.1× | 0.61 |
| Cellectar Biosciences, Inc. · NASDAQ:CLRB | US$8.00M | −US$15.05M | n/a | n/a | n/a | 0.4× | n/a | 0.1× | 1.71 |
| Immuron Limited · ASX:IMC | US$7.91M | US$1.94M | n/a | 0.4× | n/a | 1.1× | −49.8% | 0.0× | n/a |
| Phio Pharmaceuticals Corp. · NASDAQ:PHIO | US$7.84M | −US$2.77M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 1.24 |
| Vivesto AB · OMXSTO:VIVE | US$7.76M | US$6.12M | n/a | n/a | n/a | 0.5× | n/a | 0.0× | n/a |
| Median of the others | US$8.17M | US$408,090 | 6.5× | 0.7× | −49.8% | 0.0× | 1.15 |
Forecasts
3 strong buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 6.33 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.79 · 2 analysts
- Revenue, year to Dec 2026
- 418.8K · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Sabrina Martucci Johnson | Chief Executive Officer & President |
| Elizabeth Proos | Vice President, Product Development |
| Jennifer Kiang | Vice President, Corporate Affairs and Development |
| Jessica Hatheway | Vice President, Clinical Operations |
| Mark Walters | Vice President, Operations |
| Nicolas Pacelli | Vice President, Alliance Management and Business Development |
| Robert Charboneau | Vice President, Manufacturing & Supply Chain |
| David Friend | Chief Scientific Officer |
| MarDee Haring-Layton | Chief Accounting Officer |
Board
| Director | Role |
|---|---|
| Gregory Matz | Chair of the Audit |
| Susan L. Kelley | Chair of the Nominating and Governance |
| William H. Rastetter | Chairman of the Board |
| Jessica Grossman | Director |
| Robin Steele | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Dare Bioscience (NASDAQ:DARE) Q3 2026 Earnings Call | Mon, Nov 16, 2026 · 4:30 PM ET | Replay |
| Dare Bioscience (NASDAQ:DARE) Q2 2026 Earnings Call | Thu, Aug 13, 2026 · 4:30 PM ET | Replay |
| Dare Bioscience (NASDAQ:DARE) Q1 2026 Earnings Call | Thu, May 14, 2026 · 4:30 PM ET | Replay |
| Dare Bioscience (NASDAQ:DARE) Q4 2025 Earnings Call | Thu, Mar 26, 2026 · 4:30 PM ET | Replay |
| Dare Bioscience (NASDAQ:DARE) Q3 2025 Earnings Call | Thu, Nov 13, 2025 · 4:30 PM ET | Replay |
| Dare Bioscience (NASDAQ:DARE) Q2 2025 Earnings Call | Thu, Aug 14, 2025 · 4:30 PM ET | Replay |
| Dare Bioscience (NASDAQ:DARE) Q1 2025 Earnings Call | Tue, May 13, 2025 · 4:30 PM ET | Replay |
| Dare Bioscience (NASDAQ:DARE) Q4 2024 Earnings Call | Mon, Mar 31, 2025 · 4:30 PM ET | Replay |
| Dare Bioscience (NASDAQ:DARE) Q3 2024 Earnings Call | Thu, Nov 14, 2024 · 4:30 PM ET | Replay |
| Dare Bioscience (NASDAQ:DARE) Q2 2024 Earnings Call | Mon, Aug 12, 2024 · 4:30 PM ET | Replay |
All 26 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 16, 2026 · After close | −26.6% |
| Q2 2026 | Aug 13, 2026 · After close | −32.1% |
| Q1 2026 | May 14, 2026 · After close | −24.1% |
| Q4 2025 | Mar 27, 2026 | +21.2% |
| Q3 2025 | Nov 13, 2025 · After close | −1.6% |
| Q2 2025 | Aug 14, 2025 · After close | +6.3% |
| Q1 2025 | May 13, 2025 · After close | 0.0% |
| Q4 2024 | Mar 26, 2025 · Before open | −0.1% |
| Q3 2024 | Nov 14, 2024 · After close | −10.0% |
| Q2 2024 | Aug 12, 2024 · After close | +20.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 14, 2024 · Before open | −0.1% |
| Q4 2023 | Mar 28, 2024 · Before open | −10.7% |
| Q3 2023 | Nov 9, 2023 · After close | +0.3% |
| Q2 2023 | Aug 10, 2023 · Before open | −2.3% |
| Q1 2023 | May 11, 2023 · Before open | 0.0% |
| Q4 2022 | Mar 30, 2023 · Before open | +1.9% |
| Q3 2022 | Nov 10, 2022 · Before open | −2.2% |
| Q2 2022 | Aug 9, 2022 · Before open | −2.4% |
| Q1 2022 | May 12, 2022 · Before open | +9.6% |
| Q4 2021 | Mar 31, 2022 · Before open | +1.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (October 2026) | Investor deck | 40 slides | Oct 1, 2026 |
| Investor Presentation (July 2026) | Investor deck | 39 slides | Jul 13, 2026 |
| Investor Presentation (June 2026) | Investor deck | 38 slides | Jun 22, 2026 |
| Investor Presentation (April 2026) | Investor deck | 36 slides | Apr 22, 2026 |
| Investor Presentation (March 2026) | Investor deck | 30 slides | Mar 2, 2026 |
| Investor Presentation (January 2026) | Investor deck | 30 slides | Jan 6, 2026 |
| Investor Presentation (September 2025) | Investor deck | 49 slides | Sep 2, 2025 |
| Investor Presentation (June 2025) | Investor deck | 45 slides | Jun 9, 2025 |
| Investor Presentation (February 2025) | Investor deck | 41 slides | Feb 10, 2025 |
| Investor Presentation (January 2025) | Investor deck | 39 slides | Jan 13, 2025 |
Show 50 decks
This page holds 50 of 55 decks. Open Decks
Financings
| Raise | Date |
|---|---|
| Registered direct offering of common stock (or pre-funded warrants), with concurrent private placement of Series A and Series B warrants Announced: US$6M · US$1.37 a share · Warrants at US$1.37 for 60 months · Ladenburg Thalmann & Co. Inc. Dealers: Ladenburg Thalmann & Co. Inc. (lead) | Aug 17, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as Cerulean Pharma Inc. Priced at US$7.00 a share on Apr 10, 2014.
- Price
- US$7.00 a share
- Shares offered
- 8,500,000 shares of common stock
- Offering size
- US$59.5 million
- Underwriters' option
- Up to 1,275,000 more shares
- Underwriters
- Leerink Partners, Canaccord Genuity, JMP Securities, Wedbush PacGrow Life Sciences · In the order on the cover
- Shares delivered
- On or about Apr 15, 2014
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jan 30, 2014 |
| Filed publicly | Mar 10, 2014 |
| Amended twice | Newest Mar 31, 2014 |
| Shares registered with an exchange | Apr 4, 2014 |
| Declared effective by the SEC | Apr 10, 2014 |
| Final prospectus, with the price | Apr 14, 2014 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Apr 14, 2014 |
| EFFECT · Notice that a registration is effective | Apr 10, 2014 |
| FWP · Free writing prospectus | Apr 10, 2014 |
| CORRESP · Letter to the SEC | Apr 7, 2014 |
| CORRESP · Letter to the SEC | Apr 7, 2014 |
| 8-A12B · Registration of shares for listing on an exchange | Apr 4, 2014 |
| S-1/A · Registration statement, amended | Mar 31, 2014 |
| CERTNAS · Nasdaq's certificate of listing | Mar 28, 2014 |
| S-1/A · Registration statement, amended | Mar 28, 2014 |
| UPLOAD · Letter from the SEC | Mar 25, 2014 |
All 14 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Mar 21, 2014 |
| S-1 · Registration statement | Mar 10, 2014 |
| UPLOAD · Letter from the SEC | Mar 4, 2014 |
| DRS · Draft registration statement | Jan 30, 2014 |
Open IPO · From the cover of the final prospectus (424B4) filed Apr 14, 2014
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.03M | 9.78K | 2.81M | 10.0M | 0 | 0 | 0 | 0 | 0 | 766.0K |
| Cost of revenue | 295.8K | 0 | 21.6M | 47.6K | 100.0K | 83.3K | 11.1K | 625.0K | 0 | 400.0K |
| Gross profit | -1.42M | -14.3M | -18.8M | 10.0M | -100.0K | -83.3K | -11.1K | -2.44K | 0 | 366.0K |
| Research and development | 5.52M | 14.3M | 21.5M | 30.0M | 30.6M | 20.8M | 8.55M | 6.41M | 984.7K | 72.7K |
| Selling, general and administrative | 8.76M | 9.16M | 11.3M | 11.2M | 7.79M | 6.11M | 5.80M | 5.28M | 2.71M | 10.4M |
| Operating income | -13.6M | -23.5M | -30.9M | -31.4M | -39.1M | -27.4M | -14.3M | -16.9M | -11.2M | -630.6K |
| Depreciation and amortization | 1.63M | 42.3K | 38.4K | 24.2K | 26.4K | 43.2K | 11.1K | 2.44K | 0 | 261.0K |
| EBITDA | -11.9M | -23.4M | -30.9M | -31.4M | -39.0M | -27.4M | -14.3M | -16.9M | -11.2M | -369.6K |
| Interest expense | 822.7K | 437.8M | 372.4K | 0 | 0 | 0 | 322.6K | 42.1K | ||
| Income before tax | -13.5M | -4.05M | -30.2M | -30.9M | -38.7M | -27.4M | -14.3M | -16.8M | -11.5M | -673.0K |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.20K | 0 | 86.0K |
| Net income | -13.4M | -4.05M | -30.2M | -30.9M | -38.7M | -27.4M | -14.3M | -16.7M | -11.5M | -672.7K |
| Earnings per share, basic | -1.20 | -0.48 | -4.15 | -0.37 | -0.63 | -0.91 | -0.97 | -1.57 | 3.56 | -0.81 |
| Earnings per share, diluted | -1.20 | -0.48 | -4.15 | -0.37 | -0.63 | -0.91 | -0.97 | -1.57 | 3.56 | -0.81 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 24.7M | 15.7M | 10.5M | 34.7M | 51.7M | 4.67M | 4.78M | 6.81M | 7.56M | 44.6K |
| Short-term investments | 15.7B | 0 | 0 | |||||||
| Receivables | 573.1K | 230.0K | 949.2K | 1.70M | 0 | 460.2K | 555.2K | 31.0K | 284.2K | 823.0K |
| Inventory | -2.47B | -1.85B | -1.11B | -402.7M | 311.6K | -1.84M | ||||
| Current assets | 27.1M | 18.4M | 17.5M | 43.0M | 55.3M | 6.98M | 6.44M | 7.24M | 8.35M | 44.6K |
| Property, plant and equipment | 1.56M | 1.34M | 656.0K | 64.9K | 26.0K | 37.9K | 63.5K | 9.40K | 0 | 668.0K |
| Goodwill | 0 | 5.20M | 0 | |||||||
| Total assets | 32.5M | 22.1M | 21.3M | 43.8M | 55.8M | 7.55M | 7.44M | 7.83M | 14.3M | 44.6K |
| Accounts payable | 1.20M | 1.46M | 3.39M | 2.03M | 2.10M | 1.02M | 1.08M | 459.7K | 308.2K | 1.45M |
| Current liabilities | 23.7M | 21.6M | 20.5M | 31.6M | 16.1M | 7.66M | 5.61M | 1.09M | 966.7K | 755.2K |
| Long-term debt | 0 | 4.44M | ||||||||
| Total debt | 2.66M | 4.05K | 1.40M | 488.7K | 270.5K | 756.8K | 800.5K | 12.8M | ||
| Total liabilities | 29.6M | 28.1M | 26.3M | 32.7M | 17.1M | 8.70M | 7.00M | 1.10M | 967.0K | 755.2K |
| Shareholders' equity | 2.84M | -6.01M | -5.05M | 11.1M | 38.8M | -1.15M | 440.8K | 6.73M | 13.3M | -710.6K |
| Shares outstanding | 14.5M | 8.70M | 8.33M | 84.8M | 83.9M | 41.6M | 19.7M | 11.4M | 6.05M | 910.0K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -9.89M | 5.47M | -38.9M | -18.1M | -28.8M | -25.2M | -13.3M | -10.3M | -2.54M | -372.3K |
| Capital spending | -385.3K | -573.0K | -629.4K | -63.1K | -14.5K | -17.6K | 0 | -11.8K | 0 | -535.0K |
| Free cash flow | -10.3M | 4.90M | -39.5M | -18.2M | -28.8M | -25.3M | -13.3M | -10.3M | -2.54M | -907.3K |
| Cash from investing | -385.3K | -573.0K | -629.4K | -63.1K | -14.5K | -17.6K | 6.14M | -518.8K | 9.92M | -418.0K |
| Cash from financing | 19.3M | 354.5K | 15.6M | 1.34M | 75.8M | 25.1M | 5.15M | 10.1M | 155.0K | 197.5K |
| Dividends paid | -6.86M | -789.6M | 0 | 0 | ||||||
| Share buybacks | 24.8M | 5.15M | 10.1M | 0 | 918.0K | |||||
| Change in cash | 9.01M | 5.19M | -23.9M | -17.0M | 47.0M | -110.6K | -2.03M | -754.0K | 7.52M | -174.8K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 20, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 19, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 16, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 16, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2026 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | Oct 27, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Oct 6, 2026 | Meeting notice | SEC |
| 8-K · Current report | Oct 2, 2026 | Current report | SEC |
| 8-K · Current report | Oct 1, 2026 | Current report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| PRE 14A · Preliminary proxy statement | Sep 23, 2026 | Meeting notice | SEC |
| 8-K · Current report | Sep 11, 2026 | Current report | SEC |
| 8-K · Current report | Sep 9, 2026 | Current report | SEC |
| 424B3 · Prospectus | Sep 4, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Sep 4, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 28, 2026 | Big-stake notice | SEC |
| S-1 · Registration statement | Aug 26, 2026 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 24, 2026 | Big-stake notice | SEC |
| D | Aug 19, 2026 | Other filings | SEC |
| 253G2 | Aug 19, 2026 | Other filings | SEC |
| 8-K · Current report | Aug 17, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Aug 17, 2026 | Offer document | SEC |
| 8-K · Current report | Aug 13, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Jul 24, 2026 | Current report | SEC |
| 253G2 | Jul 17, 2026 | Other filings | SEC |
| 8-K · Current report | Jul 17, 2026 | Current report | SEC |
| 8-K · Current report | Jul 13, 2026 | Current report | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Jun 23, 2026 | Offer document | SEC |
| 8-K · Current report | Jun 22, 2026 | Current report | SEC |
| 8-K · Current report | Jun 12, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| DEFA14A · Additional proxy material | Jun 1, 2026 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Jun 1, 2026 | Meeting notice | SEC |
| 8-K · Current report | May 18, 2026 | Financing | SEC |
| 253G2 | May 14, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | May 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2026 | Results | SEC |
| 8-K · Current report | May 7, 2026 | Financing | SEC |
| ARS · Annual report to shareholders | Apr 28, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 28, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 22, 2026 | Current report | SEC |
| 8-K · Current report | Apr 20, 2026 | Financing | SEC |
| 8-K · Current report | Apr 17, 2026 | Management or board change | SEC |
| PRE 14A · Preliminary proxy statement | Apr 17, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 13, 2026 | Financing | SEC |
| QUALIF | Apr 2, 2026 | Other filings | SEC |
| 1-A POS | Mar 27, 2026 | Other filings | SEC |
| 253G2 | Mar 27, 2026 | Other filings | SEC |
| 10-K · Annual report | Mar 26, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 26, 2026 | Results | SEC |
| 8-K · Current report | Mar 17, 2026 | Financing | SEC |
| 8-K · Current report | Mar 9, 2026 | Financing | SEC |
| 8-K · Current report | Mar 2, 2026 | Current report | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 29, 2026 | Financing | SEC |
| 253G1 | Jan 7, 2026 | Other filings | SEC |
| 8-K · Current report | Jan 6, 2026 | Current report | SEC |
| QUALIF | Jan 6, 2026 | Other filings | SEC |
| 1-A/A | Dec 29, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Dec 23, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Dec 1, 2025 | Current report | SEC |
| 1-A | Nov 25, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 6, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 4, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 2, 2025 | Current report | SEC |
| S-8 · Registration statement for employee plans | Aug 14, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2025 | Results | SEC |
| 8-K · Current report | Jul 25, 2025 | Current report | SEC |
| 8-K · Current report | Jul 18, 2025 | Current report | SEC |
| 8-K · Current report | Jul 14, 2025 | Current report | SEC |
| 4 · Change in ownership | Jul 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 10, 2025 | Insider trade | SEC |
| 8-K · Current report | Jul 9, 2025 | Management or board change | SEC |
| 8-K · Current report | Jun 25, 2025 | Current report | SEC |
| DEFA14A · Additional proxy material | Jun 12, 2025 | Meeting notice | SEC |
| 8-K · Current report | Jun 9, 2025 | Current report | SEC |
| 10-Q · Quarterly report | May 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 24, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 24, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 24, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 11, 2025 | Current report | SEC |
| 10-K · Annual report | Mar 31, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 31, 2025 | Results | SEC |
| 8-K · Current report | Feb 14, 2025 | Current report | SEC |
| 8-K · Current report | Feb 10, 2025 | Current report | SEC |
| 4 · Change in ownership | Jan 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 31, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 13, 2025 | Current report | SEC |
| 8-K · Current report | Dec 16, 2024 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Nov 27, 2024 | Other filings | SEC |
| 424B3 · Prospectus | Nov 26, 2024 | Offer document | SEC |
| D | Nov 22, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 22, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Nov 19, 2024 | Other filings | SEC |
| S-1 · Registration statement | Nov 15, 2024 | Offer document | SEC |
| 8-K · Current report | Nov 14, 2024 | Results | SEC |
| 10-Q · Quarterly report | Nov 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Oct 25, 2024 | Current report | SEC |
| 8-K · Current report | Oct 23, 2024 | Material contract | SEC |
| 8-K · Current report | Oct 21, 2024 | Material contract | SEC |
| UPLOAD · Letter from the SEC | Oct 8, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 10, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 30, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2024 | Results | SEC |
| 8-K · Current report | Jul 19, 2024 | Current report | SEC |
| 8-K · Current report | Jun 27, 2024 | Current report | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 7, 2024 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2024 | Results | SEC |
| EFFECT · Notice that a registration is effective | May 13, 2024 | Other filings | SEC |
| 424B5 · Prospectus | May 10, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | May 8, 2024 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | May 2, 2024 | Other filings | SEC |
| 424B3 · Prospectus | May 1, 2024 | Offer document | SEC |
| 8-K · Current report | Apr 30, 2024 | Acquisition or disposal | SEC |
| CORRESP · Letter to the SEC | Apr 29, 2024 | Other filings | SEC |
| ARS · Annual report to shareholders | Apr 26, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 26, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 26, 2024 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 16, 2024 | Meeting notice | SEC |
| UPLOAD · Letter from the SEC | Apr 3, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 3, 2024 | Other filings | SEC |
| S-3 · Registration statement | Mar 29, 2024 | Offer document | SEC |
| S-3 · Registration statement | Mar 29, 2024 | Offer document | SEC |
| 424B5 · Prospectus | Mar 28, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 28, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 28, 2024 | Results | SEC |
| 4 · Change in ownership | Mar 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 14, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 29, 2024 | Insider trade | SEC |
| 8-K · Current report | Jan 26, 2024 | Management or board change | SEC |
| 8-K · Current report | Jan 19, 2024 | Current report | SEC |
| 8-K · Current report | Jan 8, 2024 | Current report | SEC |
| D | Dec 26, 2023 | Other filings | SEC |
| 8-K · Current report | Dec 26, 2023 | Material contract | SEC |
| 8-K · Current report | Dec 20, 2023 | Current report | SEC |
| 8-K · Current report | Nov 9, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Nov 9, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 9, 2023 | Results | SEC |
| 8-K · Current report | Nov 1, 2023 | Current report | SEC |
| 8-K · Current report | Oct 16, 2023 | Current report | SEC |
| 8-K · Current report | Sep 11, 2023 | Current report | SEC |
| 424B5 · Prospectus | Aug 30, 2023 | Offer document | SEC |
| 8-K · Current report | Aug 30, 2023 | Material contract | SEC |
| 10-Q · Quarterly report | Aug 10, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 10, 2023 | Results | SEC |
| 8-K · Current report | Jul 21, 2023 | Current report | SEC |
| 8-K · Current report | Jul 5, 2023 | Material contract | SEC |
| 8-K · Current report | Jun 22, 2023 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 21, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2023 | Insider trade | SEC |
| 8-K · Current report | Jun 5, 2023 | Current report | SEC |
| 10-Q · Quarterly report | May 11, 2023 | Quarterly report | SEC |
| 8-K · Current report | May 11, 2023 | Results | SEC |
| ARS · Annual report to shareholders | May 1, 2023 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 27, 2023 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 27, 2023 | Meeting notice | SEC |
| 424B5 · Prospectus | Mar 31, 2023 | Offer document | SEC |
| 8-K · Current report | Mar 31, 2023 | Material contract | SEC |
| 10-K · Annual report | Mar 30, 2023 | Annual report | SEC |
| 8-K · Current report | Mar 30, 2023 | Results | SEC |
| 8-K · Current report | Mar 13, 2023 | Current report | SEC |
| 8-K · Current report | Feb 6, 2023 | Current report | SEC |
| 8-K · Current report | Jan 27, 2023 | Current report | SEC |
| 4 · Change in ownership | Jan 26, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2023 | Insider trade | SEC |
| 8-K · Current report | Jan 25, 2023 | Current report | SEC |
This page holds 200 of 783 filings. Open Filings
Cap table
Built by 6ix from Dare Bioscience, Inc.’s releases · as of Nov 13, 2026
- Common shares
- 19,669,083
- Fully diluted
- 19,669,083
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 19,669,083 | Nov 13, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 13, 2026 | 19,669,083 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Cheryl R. Blanchard Other companies: Xilio Therapeutics, Inc. (Board Member · Since at least Apr 15, 2026); Vigil Neuroscience Inc (Director · Since at least Jan 6, 2022); Anika Therapeutics Inc. (Director · Since at least Aug 31, 2018); Neuronetics, Inc. (Director · Feb 13, 2019 – May 26, 2020 · Past); SeaSpine Holdings Corp (Director · Jul 1, 2015 – May 30, 2018 · Past); Zimmer Biomet Holdings, Inc. (Sr. VP, Chief Scientific Off. · Feb 17, 2011 – Mar 19, 2012 · Past) | Director · Nov 20, 2019 – Jun 21, 2023 · Past |
| William McKee Other companies: Assertio Holdings, Inc. (Director · Since at least May 19, 2020); C4 Therapeutics, Inc. (Chief Financial Officer · Oct 1, 2020 – Oct 6, 2020 · Past); Rein Therapeutics, Inc. (Director · Jun 19, 2019 – Jun 15, 2022 · Past); Depomed Inc (Director · Mar 28, 2017 – May 8, 2018 · Past); Auxilium Pharmaceuticals Inc (Director · Mar 18, 2009 – Jan 29, 2015 · Past); Barr Pharmaceuticals Inc (EVP, CFO · Jan 3, 2006 – Dec 23, 2008 · Past) | Director · Apr 10, 2014 – Jan 3, 2017 · Past |
| Stuart Arbuckle Other companies: Praxis Precision Medicines, Inc. (Director · Since at least Jan 8, 2026); Alnylam Pharmaceuticals, Inc. (Director · Since at least Jan 5, 2026); Rhythm Pharmaceuticals, Inc. (Director · Since at least Jul 23, 2019); Vertex Pharmaceuticals Incorporated (EVP, COO · Since at least May 25, 2016); ImmunoGen Inc (Director · Jan 23, 2018 – Feb 12, 2024 · Past) | Director · Jun 22, 2016 – Jan 3, 2017 · Past |
| Alejandra Carvajal Other companies: CytomX Therapeutics, Inc. (Chief Legal Officer · Since at least Aug 3, 2026); Mersana Therapeutics Inc (SVP, Chief Legal Officer · Since at least Apr 26, 2021); Momenta Pharmaceuticals Inc (Chief Legal Officer · Oct 5, 2018 – Oct 1, 2020 · Past) | VP, General Counsel · Jun 26, 2015 – Jan 5, 2017 · Past |
| David R Walt Other companies: Quanterix Corporation (Director · Since at least Dec 6, 2017); Exicure, Inc. (Director · Sep 26, 2017 – Jun 4, 2020 · Past); Illumina, Inc. (Director · Apr 2, 2007 – Apr 7, 2016 · Past) | Director · Feb 23, 2015 – Jan 3, 2017 · Past |
| William H. Rastetter Other companies: Iambic Therapeutics, Inc. (Board Chair · Since at least Oct 16, 2026); Neurocrine Biosciences, Inc. (Director · Since at least May 21, 2026); Fate Therapeutics, Inc. (Chairman · Since at least May 5, 2026) | Chairman of the Board · Since at least Jun 30, 2026 |
| Adrian M. Senderowicz Other companies: Puma Biotechnology Inc (Director · Since at least Aug 11, 2015); Constellation Pharmaceuticals Inc (Chief Medical Officer · Jul 18, 2018 – May 12, 2020 · Past) | SVP, Chief Medical Officer · Sep 4, 2015 – Jan 5, 2017 · Past |
| Lisa Walters-Hoffert Other companies: Kiora Pharmaceuticals, Inc. (Director · Since at least Jul 1, 2024); Flux Power Holdings, Inc. (Director · Since at least Jun 28, 2019) | Chief Financial Officer · Jul 19, 2017 – Jan 24, 2023 · Past |
| Steven Edward Hall Other companies: Kymera Therapeutics, Inc. (Director · Aug 20, 2020 – Jun 16, 2021 · Past); Forma Therapeutics Holdings Inc (Director · Jun 18, 2020 – Jun 23, 2020 · Past) | Director · Apr 10, 2014 – Jun 22, 2016 · Past |
| Christopherd T Guiffre Other companies: Pear Therapeutics Inc (CFO, COO, Treas., & Asst. Sec. · Dec 3, 2021 – Feb 15, 2023 · Past) | Chief Executive Officer, Director · Jun 30, 2016 – Jan 6, 2017 · Past |
All 26 people
| Person | Seat |
|---|---|
| MarDee Haring-Layton Other companies: e.Digital Corporation (Chief Financial Officer · Dec 5, 2011 – Mar 30, 2015 · Past) | Chief Accounting Officer · Since at least Jan 26, 2024 |
| Roger Hawley Other companies: Zogenix Inc (Director · Jul 13, 2016 – Mar 29, 2019 · Past) | Director · Jul 19, 2017 – Jun 13, 2019 · Past |
| David Friend | Chief Scientific Officer · Since at least Sep 14, 2026 |
| Edward Graeme Garmey | Sr. VP, Chief Medical Officer · Apr 10, 2014 – Feb 5, 2015 · Past |
| Elizabeth Proos | Vice President, Product Development · Since at least Nov 4, 2026 |
| Gregory Matz | Chair of the Audit · Since at least Jul 2, 2026 |
| Jennifer Kiang | Vice President, Corporate Affairs and Development · Since at least Nov 4, 2026 |
| Jessica Grossman | Director · Since at least Jun 30, 2026 |
| Jessica Hatheway | Vice President, Clinical Operations · Since at least Nov 4, 2026 |
| John A Fair | Chief Commercial Officer · Mar 6, 2020 – Mar 12, 2024 · Past |
| Mark Walters | Vice President, Operations · Since at least Nov 4, 2026 |
| Nicolas Pacelli | Vice President, Alliance Management and Business Development · Since at least Nov 4, 2026 |
| Robert Charboneau | Vice President, Manufacturing & Supply Chain · Since at least Nov 4, 2026 |
| Robin Steele | Director · Since at least Jul 19, 2017 |
| Sabrina Martucci Johnson | Chief Executive Officer & President · Since at least Oct 30, 2026 |
| Susan L. Kelley | Director · Since at least Jun 30, 2026 |
Log in to ask 6ix AI your own questions about Dare Bioscience, Inc.